Evidence map›Paper›PMID 40833194›Full record

ArticleBiomaterials science2025

Lung-targeting lipid nanoparticle-mediated sparstolonin B delivery improves acute lung injury.

Qinghe Meng, David O Popoola, Chunyan Wang, Yuqin Men, Yuqi Song, Zhi Cao, Adam Novak, Yamin Li, Robert N Cooney

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Qinghe MengDepartments of Surgery, State University of New York, Upstate Medical University, USA. cooneyr@upstate.edu.
David O PopoolaDepartment of Pharmacology, State University of New York, Upstate Medical University, USA. liyam@upstate.edu.
Chunyan WangDepartments of Surgery, State University of New York, Upstate Medical University, USA. cooneyr@upstate.edu.
Yuqin MenDepartment of Pharmacology, State University of New York, Upstate Medical University, USA. liyam@upstate.edu.
Yuqi SongDepartments of Surgery, State University of New York, Upstate Medical University, USA. cooneyr@upstate.edu.
Zhi CaoDepartment of Pharmacology, State University of New York, Upstate Medical University, USA. liyam@upstate.edu.
Adam NovakDepartments of Surgery, State University of New York, Upstate Medical University, USA. cooneyr@upstate.edu.
Yamin LiDepartment of Pharmacology, State University of New York, Upstate Medical University, USA. liyam@upstate.edu.ORCID http://orcid.org/0000-0002-5535-1807
Robert N CooneyDepartments of Surgery, State University of New York, Upstate Medical University, USA. cooneyr@upstate.edu.

Funding

Development of Sulfonium- and Phosphonium-based Cationic Lipid Materials for mRNA DeliveryR03EB032579 · NIBIB · UPSTATE MEDICAL UNIVERSITY · PI LI, YAMIN · 2022 to 2023
$163k
NIBIB NIH HHS R03 EB032579
6 · The paper itself

Abstract

Acute respiratory distress syndrome (ARDS), a severe manifestation of acute lung injury (ALI), is characterized by high morbidity and mortality, with limited therapeutic options. Sparstolonin B (SsnB), a selective antagonist of Toll-like receptors (TLR)-2 and TLR-4 with significant anti-inflammatory activity, has been studied in various diseases. However, its potential for targeted delivery to lung tissues in the treatment of ARDS/ALI remains an underexplored area warranting further investigation. Here, we report the development of a lung-targeting sulfonium lipid nanoparticle (sLNP)-mediated SsnB delivery system in a murine model of lipopolysaccharide (LPS)-induced ALI. Comprehensive analyses of serum, bronchoalveolar lavage fluid (BALF), and lung tissues post-injury revealed that SsnB-loaded sLNP (SsnB/sLNP) significantly mitigated lung injury. This was evidenced by improved lung histology, reduced macrophage counts and neutrophil infiltration in BALF, and decreased levels of pro-inflammatory cytokines, including TNF-α, IL-1β and IL-6, in both BALF and serum. Mechanistic studies further demonstrated that the therapeutic effects of SsnB were mediated through the inhibition of the NF-κB signaling pathway. These findings highlight the potential of lung-targeting sLNP-mediated SsnB delivery as a promising therapeutic strategy for ALI and ARDS.

Indexed as

Acute Lung InjuryLipidsLungNanoparticlesSulfonamidesAnimalsBronchoalveolar Lavage FluidCytokinesDisease Models, AnimalDrug Delivery SystemsHeterocyclic Compounds, 4 or More RingsLipopolysaccharidesMaleMiceMice, Inbred C57BLNF-kappa BCytokinesHeterocyclic Compounds, 4 or More RingsLipidsLipopolysaccharidesNF-kappa Bsparstolonin BSulfonamides

Identifiers

PMID40833194
PMCPMC12954737

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.